Zhaoke Ophthalmic (å ē§ē¼ē§) Pre-IPO: Beware of Aggressive "Guidance"
We did research on its key competitor in the CsA segment and think that Frost & Sullivan grossly underestimates the competition and overestimates...
542 Views
Zhaoke Opthalmology IPO: Promising Drug Candidates; but Commercialisation May Take Longer
Zhaoke's strong drug pipeline demonstrates strong growth potential and some of the companyās drug candidates have the potential to become market...
329 Views
Zhaoke Ophthalmology IPO Initiation: The Eyes Have It
Zhaoke is pre-marketing an HKEx IPO to raise $200 million, according to press reports. Overall, we believe that Zhaokeās drug assets are attractive.
427 Views
Zhaoke Ophthalmic (å ē§ē¼ē§) Pre-IPO: Thoughts on Valuation
In this note, we provide a forecast on Zhaoke Ophthalmic's two core products CsA ophthalmic gel and the ZKY001 and an SOTP based valuation for the...
575 Views
ECM Weekly (5th April 2021) - Nayuki, Peter Warren, Linklogis, Zhaoke Ophthalmic, Macrotech Dev
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
502 Views